On April 21, 2026, Amneal Pharmaceuticals agreed to acquire Kashiv BioSciences for $375 million in cash and 28.9 million shares, plus potential future payments of $350 million based on product milestones. This major acquisition is significant for the company and involves complex share arrangements.